It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
OBJECTIVES: To assess the usefulness of adding PET/CT as a preoperative test for determining the extent of endometrial cancer and discriminating low- and high-risk patients to identify candidates for surgical staging.
MATERIAL AND METHODS: We retrospectively reviewed 86 patients with pathologically proven endometrial cancer who had undergone preoperative ¹⁸F-FDG PET/CT. The prognostic relationships between PET/CT parameters and pathology reports were assessed.
RESULTS: The SUVmax was significantly higher in patients with FIGO stage IB or higher compared with those with stage IA; for stage III–IV compared with stage I–II; and for patients with lymph node metastasis compared with those without lymph node metastasis. Using 6.70 as a cut-off for SUVmax, low-risk patients can be identified with a sensitivity of 92.9%.
CONCLUSIONS: PET/CT imaging can be used not only for determining malignancy and lymph node involvement but also for determining candidates for surgical staging with high sensitivity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Zekai Tahir Burak Women Health Education and Research Hospital, Gynecologic Oncology Department, Ankara, Turkey. [email protected]